Sarcoma
Welcome,         Profile    Billing    Logout  
 506 Companies   302 Products   302 Products   167 Mechanisms of Action   1360 Trials   122555 News 


«12...1819202122232425262728...15261527»
  • ||||||||||  AiTan (rivoceranib) / HLB Bio Group
    Trial completion, Combination therapy:  Apatinib With Ifosfamide Plus Etoposide for Relapsed or Refractory Osteosarcoma (OAIE) (clinicaltrials.gov) -  May 13, 2024   
    P2,  N=81, Completed, 
    Trial completion date: Apr 2024 --> Apr 2026 | Recruiting --> Suspended | Trial primary completion date: Apr 2023 --> Apr 2026 Recruiting --> Completed
  • ||||||||||  Journal:  Self-Assembled Hydrogel Membranes with Structurally Tunable Mechanical and Biological Properties. (Pubmed Central) -  May 13, 2024   
    Cytocompatibility and cell adhesion improved with the introduction of ChNCs. The extracted ChNCs are used as a reinforcing nanofiller to enhance the performance properties of tropocollagen hydrogel membranes and provide new insights into the design of novel LHMs that could be used for various medical applications, such as control of drug release in the skin and bone tissue regeneration.
  • ||||||||||  Review, Journal, Metastases:  Metastatic sarcomas of the oral cavity: A systematic review. (Pubmed Central) -  May 13, 2024   
    Although OMSs show a high occurrence in the 7th decade of the life, the average age of patients with oral involvement is lower than the overall metastatic lesions. OMSs may present as widespread disease with poor prognosis.
  • ||||||||||  Journal:  Epithelioid hemangioma of the acromion causing shoulder pain: a case report. (Pubmed Central) -  May 13, 2024   
    A 69-year-old male who presented with intractable shoulder pain caused by epithelioid hemangioma in the acromion of the scapula was treated with tumor curettage. This paper reports a good result with a review of the relevant literature.
  • ||||||||||  Journal, IO biomarker:  HOXB5 promotes the progression and metastasis of osteosarcoma cells by activating the JAK2/STAT3 signalling pathway. (Pubmed Central) -  May 13, 2024   
    Silencing HOXB5 reduced the proliferation, migration and invasion of osteosarcoma cells; prevented the progression and metastasis of tumours in tumour-bearing nude mice; and reduced the activation of key proteins in the JAK2/STAT3 signalling pathway. Through the JAK2/STAT3 signalling pathway, HOXB5 plays a crucial role in the malignant progression of osteosarcoma and is a promising target for osteosarcoma treatment.
  • ||||||||||  Biomarker, Journal:  Differential expression of DMD transcripts as a novel prognostic biomarker in histologically diverse mesotheliomas. (Pubmed Central) -  May 13, 2024   
    Further studies are needed to understand the role of specific dystrophin transcripts in cancer and TME cells, and their implications in the pathogenesis and progression of mesothelioma. Identifying patients at risk of poor survival based on DMD transcript expression can guide treatment strategies in mesothelioma, informing decisions regarding treatment intensity, follow-up schedules, eligibility for clinical trials, and ultimately, end-of-life care planning.
  • ||||||||||  Biomarker, Journal:  Prolonged survival and novel prognostic factors in women with pleural mesothelioma treated with extended pleurectomy decortication. (Pubmed Central) -  May 13, 2024   
    In a univariate analysis, several factors were found to be associated with patient overall survival including MCR [hazard ratio (HR): 0.3, P<0.001], early T status (HR: 1.6, P=0.03), adjuvant therapy (HR: 0.5, P=0.006), intraoperative heated chemotherapy (IOHC) (HR: 0.8, P=0.03), age (HR: 1.02, P=0.03) and epithelioid histology (HR: 0.5, P=0.009). For women with epithelioid PM undergoing intended ePD within a multimodal setting, prolonged survival is anticipated.
  • ||||||||||  Keytruda (pembrolizumab) / Merck (MSD)
    Trial completion date, Trial primary completion date, IO biomarker:  Pembrolizumab in Treating Patients With Malignant Mesothelioma (clinicaltrials.gov) -  May 13, 2024   
    P2,  N=65, Active, not recruiting, 
    CONCLUSIONS This report highlights the challenges of post-radiation reconstructive surgery and describes how an expanded forehead flap can achieve an acceptable cosmetic outcome in a patient with a sinonasal-cutaneous fistula. Trial completion date: Mar 2024 --> Mar 2026 | Trial primary completion date: Mar 2024 --> Mar 2026
  • ||||||||||  Enrollment open:  Natural History Study of Kaposi Sarcoma (clinicaltrials.gov) -  May 12, 2024   
    P=N/A,  N=150, Recruiting, 
    Trial completion date: Jan 2025 --> Jan 2026 | Trial primary completion date: Jan 2025 --> Jan 2026 Not yet recruiting --> Recruiting
  • ||||||||||  Proleukin (aldesleukin) / Merck (MSD), Novartis, Iovance Biotherap
    Phase classification, Trial completion date, Trial primary completion date:  Aerosolized Aldesleukin in Treating Patients With Lung Metastases (clinicaltrials.gov) -  May 12, 2024   
    P1,  N=70, Active, not recruiting, 
    Not yet recruiting --> Recruiting Phase classification: P1/2 --> P1 | Trial completion date: Apr 2024 --> Apr 2026 | Trial primary completion date: Apr 2024 --> Apr 2026
  • ||||||||||  Review, Journal:  Vascular tumors of intermediate malignancy: An update. (Pubmed Central) -  May 12, 2024   
    The hemangioendotheliomas fall into several specific, clinicopathologically and genetically distinct entities, specifically epithelioid hemangioendothelioma, kaposiform hemangioendothelioma, papillary intralymphatic angioendothelioma and retiform hemangioendothelioma (hobnailed hemangioendothelioma), pseudomyogenic hemangioendothelioma, composite hemangioendothelioma, and YAP1::TFE3-fused hemangioendothelioma. The clinical, morphologic, immunohistochemical, and genetic features, and the differential diagnosis of each of these rare entities are discussed in this review.
  • ||||||||||  Review, Journal:  Dedifferentiation in bone and soft tissue sarcomas: How do we define it? What is prognostically relevant? (Pubmed Central) -  May 12, 2024   
    As a result of that review, recommendations are advocated to identify evidence-based, objective diagnostic and grading criteria for dedifferentiation that are appropriate for each tumor type. Adding such criteria will improve consistency in diagnosis worldwide, allow easier comparison of clinical research performed on dedifferentiated tumors and help communicate (to patients and clinicians) the tumors with highest risk of clinically aggressive behavior, to allow appropriate and personalized treatment planning.
  • ||||||||||  Review, Journal:  Rhabdomyosarcoma: Updates on classification and the necessity of molecular testing beyond immunohistochemistry. (Pubmed Central) -  May 12, 2024   
    New subtypes such as osseus RMS harboring TFCP2/NCOA2 fusions or RMS arising in inflammatory rhabdomyoblastic tumor have been emerging within the last decade, adding to the complexity of diagnosing skeletal muscle tumors. This review article provides an overview of classically recognized distinctive subtypes as well as new, evolving subtypes and discusses important morphologic, immunophenotypic and molecular genetic features of each subtype including recommendations for a diagnostic approach of malignant skeletal muscle neoplasms.
  • ||||||||||  Primary sarcomas of the kidney: epidemiology and therapy in adult patients (Seminar room 7-8) -  May 12, 2024 - Abstract #NORDKONGRESS2024NORDKONGRESS_116;    
    However, treatment patterns for renal sarcomas tend to follow the recommendations of the guidelines for renal cell carcinoma. We therefore recommend that a preoperative biopsy be considered for kidney tumors that are highly suspicious of sarcoma.
  • ||||||||||  Journal:  PRIMARY CHONDROSARCOMA OF THE SPINE (Pubmed Central) -  May 12, 2024   
    We therefore recommend that a preoperative biopsy be considered for kidney tumors that are highly suspicious of sarcoma. PRIMARY CHONDROSARCOMA OF THE SPINE.
  • ||||||||||  imatinib / Generic mfg.
    Journal, PARP Biomarker, Stroma:  Arbutus unedo L. Fractions Exhibit Chemotherapeutic Properties for the Treatment of Gastrointestinal Stromal Tumors. (Pubmed Central) -  May 11, 2024   
    Notably, FRs similarly impaired the viability of GIST cells and peripheral blood mononuclear cells (PBMCs), suggesting a non-specific mechanism of action. Nevertheless, despite the lack of specificity, the established FRs showed promising chemotherapeutic properties to broadly affect the viability of GIST cells, including those that are imatinib-resistant, encouraging further studies to investigate whether pyrogallol-bearing compounds could represent an alternative avenue in GISTs.
  • ||||||||||  Review, Journal:  Primary Cardiac Intimal Sarcoma: Multi-Layered Strategy and Core Role of MDM2 Amplification/Co-Amplification and MDM2 Immunostaining. (Pubmed Central) -  May 11, 2024   
    To summarize, MDM2 amplification and co-amplification, for example, with MDM4, CDK4, HMGA3, CCND3, PDGFRA, TERT, KIT, CCND3, and HDAC9, might improve the diagnosis of PCIS in addition to MDM2 immunostaining since 10-20% of these tumours are MDM2-negative. Further studies are necessary to highlight MDM2 applicability as a prognostic factor and as an element to be taken into account amid multi-layered management in an otherwise very aggressive malignancy.
  • ||||||||||  Biomarker, Journal:  Plexiform Fibromyxoma in the Stomach: Immunohistochemical Profile and Comprehensive Genetic Characterization. (Pubmed Central) -  May 11, 2024   
    Herein, we present a case of PF diagnosed in a 71-year-old male with a history of lung cancer, initially suspected to have a gastrointestinal stromal tumor (GIST) of the stomach, who subsequently underwent subtotal gastrectomy. The histopathological and molecular features of the tumor, including mutations in ABL1, CCND1, CSF1R, FGFR4, KDR, and MALAT1-GLI1 fusion, are elucidated and discussed in the context of diagnostic, prognostic, and therapeutic considerations.
  • ||||||||||  Biomarker, Journal, PD(L)-1 Biomarker, IO biomarker:  Clinical and Biologic Correlates of ADORA2A Transcriptomic Expression in Cancer. (Pubmed Central) -  May 11, 2024   
    Therefore, high ADORA2A transcript levels may be a favorable prognostic factor, unrelated to immunotherapy. Importantly, ascertaining co-expression patterns of ADORA2A with PD-1 and VISTA in individual tumors as a basis for the precision co-targeting of ADORA2A and these other checkpoint-related molecules warrants investigation in clinical trials.